These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18537019)

  • 1. Infliximab treatment in refractory Kawasaki syndrome.
    Girish M; Subramaniam G
    Indian J Pediatr; 2008 May; 75(5):521-2. PubMed ID: 18537019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS; Durán DG; Peracaula CS; Iznardi CR; Tardío JO
    An Pediatr (Barc); 2010 Nov; 73(5):268-71. PubMed ID: 20678974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of infliximab in long-lasting refractory Kawasaki disease.
    Zulian F; Zanon G; Martini G; Mescoli G; Milanesi O
    Clin Exp Rheumatol; 2006; 24(4):453. PubMed ID: 16956440
    [No Abstract]   [Full Text] [Related]  

  • 4. Infliximab treatment for pediatric refractory Kawasaki disease.
    Blaisdell LL; Hayman JA; Moran AM
    Pediatr Cardiol; 2011 Oct; 32(7):1023-7. PubMed ID: 21773835
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab for Kawasaki syndrome.
    Saji T; Kemmotsu Y
    J Pediatr; 2006 Sep; 149(3):426; author reply 426. PubMed ID: 16939768
    [No Abstract]   [Full Text] [Related]  

  • 6. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
    O'connor MJ; Saulsbury FT
    Clin Pediatr (Phila); 2007 May; 46(4):345-8. PubMed ID: 17475994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
    J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.
    Son MB; Gauvreau K; Ma L; Baker AL; Sundel RP; Fulton DR; Newburger JW
    Pediatrics; 2009 Jul; 124(1):1-8. PubMed ID: 19564276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
    J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE; Eberhard BA; Chowdhury D; Gottlieb BS
    J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.
    Hirono K; Kemmotsu Y; Wittkowski H; Foell D; Saito K; Ibuki K; Watanabe K; Watanabe S; Uese K; Kanegane H; Origasa H; Ichida F; Roth J; Miyawaki T; Saji T
    Pediatr Res; 2009 Jun; 65(6):696-701. PubMed ID: 19430379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for the treatment of Kawasaki disease.
    Matsubara T
    Pediatr Int; 2018 Sep; 60(9):775. PubMed ID: 30255976
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M
    J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin.
    Shirley DA; Stephens I
    Pediatr Infect Dis J; 2010 Oct; 29(10):978-9. PubMed ID: 20431427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.
    Oishi T; Fujieda M; Shiraishi T; Ono M; Inoue K; Takahashi A; Ogura H; Wakiguchi H
    Circ J; 2008 May; 72(5):850-2. PubMed ID: 18441471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
    Davies S; Gold-von Simson G
    Pediatr Cardiol; 2013 Oct; 34(7):1756. PubMed ID: 23771701
    [No Abstract]   [Full Text] [Related]  

  • 19. Refractory Kawasaki disease: infliximab or methotrexate therapy?
    Shin JI; Lee JS; Choi JY; Kim DS; Girish M; Subramaniam
    Indian J Pediatr; 2009 Nov; 76(11):1184; author reply 1184. PubMed ID: 20072867
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
    Stenbøg EV; Windelborg B; Hørlyck A; Herlin T
    Scand J Rheumatol; 2006; 35(4):318-21. PubMed ID: 16882598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.